What is Rogaine?
Rogaine is the brand name for topical minoxidil, a medicine used to treat androgenetic alopecia (hereditary hair loss) in both men and women. It is applied directly to the scalp and is available in two formulations — a liquid solution and a foam — at various minoxidil concentrations.
Minoxidil was originally developed as an oral antihypertensive drug. Its hair-growth stimulating properties were discovered as an unexpected side effect and subsequently investigated clinically. Topical minoxidil is now one of the most extensively studied and widely used treatments for hair loss globally, with a well-established clinical evidence base reviewed by the European Medicines Agency (EMA) and equivalent regulatory bodies.
How does Rogaine work?
Minoxidil’s precise mechanism of action in promoting hair growth is not completely characterised, but several pharmacological effects are understood:
- Vasodilation: Minoxidil is a potassium channel opener that causes peripheral vasodilation. Applied to the scalp, it increases blood flow to the hair follicle, improving the delivery of oxygen and nutrients.
- Anagen phase prolongation: Minoxidil has been shown to extend the anagen (active growth) phase of the hair cycle and shorten the telogen (resting) phase, leading to more follicles in active growth at any given time.
- Direct follicle stimulation: In vitro and in vivo evidence suggests minoxidil may also act directly on follicle cells to stimulate proliferation and inhibit apoptosis (programmed cell death).
Key distinction from finasteride: Minoxidil does not reduce DHT levels or act on the hormonal pathways that cause androgenetic alopecia. It stimulates follicle activity through vascular and direct cellular mechanisms. This means it can be effective for both men and women, and the two treatments (minoxidil and finasteride) can in some cases be used concurrently under medical supervision for complementary effects.
Who is Rogaine for?
Rogaine is approved for the topical treatment of androgenetic alopecia in:
- Men: Thinning at the vertex (crown) and mid-scalp, as characterised by Hamilton-Norwood scale grades II–V vertex.
- Women: Diffuse hair thinning across the top of the scalp (frontal, parietal, and temporal areas), as characterised by Ludwig scale grades I–II.
Rogaine may also be considered for other forms of hair loss under medical supervision, though the approved indication is androgenetic alopecia.
Rogaine is not appropriate for everyone. It should not be used by:
- People with known hypersensitivity to minoxidil or any ingredient in the product
- People with scalp conditions that may increase absorption (open sores, psoriasis, severe dermatitis)
- People with a history of allergic contact dermatitis to minoxidil
Women who are pregnant or breastfeeding should discuss risk and benefit with a doctor before using minoxidil.
Posología and Application
Rogaine is applied topically to the scalp twice daily (every 12 hours). It is available in two formulations:
Solution (Liquid)
| Concentración | Uso |
|---|---|
| 2% solution | Standard concentration, often used as starting dose or in women |
| 5% solution | Higher concentration; approved for men; may be used in women under medical supervision |
Apply 1 ml to the dry scalp in the affected area twice daily using the dropper or applicator. Spread gently with fingertips and wash hands thoroughly after application.
Foam
| Concentración | Uso |
|---|---|
| 5% foam | Standard foam formulation, approved for men; commonly used in women for ease of application |
Apply half a capful (about 1 g) to the dry scalp twice daily. Part the hair in the affected area, apply foam directly to the scalp, and gently massage in with fingertips. Wash hands after use.
Notas importantes de aplicación:
- Allow the scalp to dry completely before applying
- Do not apply to other parts of the body
- Avoid contact with eyes, nose, and mouth — if contact occurs, rinse thoroughly with water
- Do not use a hairdryer on the scalp immediately after application, as heat reduces efficacy
- Allow at least 4 hours for the product to dry before swimming or washing hair
Efectos secundarios
Como todos los medicamentos, Rogaine puede causar efectos secundarios.
Efectos secundarios frecuentes (pueden afectar a más de 1 de cada 10 personas)
- Scalp itching and irritation (more common with the solution due to propylene glycol)
- Scalp dryness or flaking
- Increased hair shedding during the first 2 to 4 weeks of treatment (telogen effluvium — a normal transitional effect)
Efectos secundarios poco frecuentes (pueden afectar hasta a 1 de cada 10 personas)
- Scalp redness (erythema) or contact dermatitis
- Unwanted facial hair growth in women (particularly if product contacts the face — the foam formulation may reduce this risk)
- Hypertrichosis (hair growth in areas other than the scalp) — uncommon at topical doses
Efectos secundarios graves pero raros
At topical doses, systemic absorption of minoxidil is minimal. However, if excessive amounts are applied or absorption is increased by scalp conditions, the following may occur:
- Cardiovascular effects: Low blood pressure, rapid heartbeat, chest pain, or fluid retention (oedema). Seek immediate medical attention if these occur.
- Severe allergic reactions: Including rash, urticaria, swelling of the face or throat, and difficulty breathing.
If you experience sudden unexplained weight gain, swelling of the hands or feet, or difficulty breathing, stop using Rogaine and contact a doctor immediately.
Rogaine vs alternatives
The primary evidence-based treatments for androgenetic alopecia are minoxidil and finasteride. They can be used independently or, in men, sometimes in combination under medical supervision.
| Treatment | Active Ingredient | Mechanism | Form | Approved For |
|---|---|---|---|---|
| Rogaine | Minoxidil | Vasodilator / follicle stimulant | Topical solution or foam | Men and women |
| Propecia | Finasteride 1 mg | 5-alpha reductase inhibitor (DHT reduction) | Oral tablet | Men only |
Diferencias clave:
- Rogaine vs Propecia: The two treatments act through entirely different mechanisms. Minoxidil stimulates hair follicle activity at the scalp level; finasteride reduces the hormonal signal (DHT) that causes follicle miniaturisation. Rogaine is suitable for both men and women; Propecia is approved for men only. Some men use both concurrently — this combination is not contraindicated, and limited clinical data suggests additive benefit — but combination therapy should be initiated under medical guidance.
- Onset and maintenance: Both treatments require sustained use to maintain results. Stopping either leads to reversal of gains within approximately 12 months. Rogaine may produce earlier visible results in terms of reduced shedding, while finasteride typically addresses the underlying progression more definitively.
- Formulation convenience: Rogaine requires twice-daily topical application; Propecia is a once-daily oral tablet. Some patients find the oral route more convenient for long-term adherence.
How to access Rogaine online in Europe
The availability of minoxidil without a prescription varies by concentration and EU member state. In many countries, 2% and 5% topical minoxidil is available without a prescription. Higher-strength formulations and oral minoxidil require a prescription.
For prescription-only minoxidil formulations, Prescrivia opera como intermediario tecnológico: no prescribimos medicamentos, no empleamos médicos ni vendemos medicamentos. Nuestra plataforma conecta a los pacientes con médicos independientes registrados en la UE que pueden realizar evaluaciones de salud en línea confidenciales.
El proceso funciona de la siguiente manera:
- Complete una evaluación de salud: Answer structured health questions covering your hair loss history, medical history, and current medications.
- Revisión médica: Un médico independiente registrado en la UE revisa su evaluación. If a prescription-strength minoxidil formulation is clinically appropriate, they may issue a prescription. If it is not appropriate, the doctor will explain why.
- Prescripción y dispensación: Si se emite una receta, se envía a una farmacia asociada autorizada de la UE, que dispensa y envía el medicamento a usted.
Importante: Prescrivia no garantiza que se emita una receta. Todas las decisiones de prescripción son tomadas de forma independiente por profesionales médicos cualificados.
Información importante de seguridad
No utilice Rogaine si usted:
- Are allergic to minoxidil, propylene glycol (in solution), or any other ingredient in the product
- Have an irritated, sunburned, or broken scalp
- Are using other topical scalp medicines without first consulting a doctor
Informe a su médico antes de using Rogaine if you have:
- Heart disease, low blood pressure, or a history of pericarditis
- Kidney or liver disease
- Any scalp condition (psoriasis, dermatitis, seborrhoeic conditions)
- Are pregnant, planning to become pregnant, or breastfeeding
Contacte con su médico si experimenta:
- Chest pain, rapid heartbeat, or dizziness after application
- Sudden unexplained weight gain or lower limb swelling
- No improvement after 4 months of consistent twice-daily use
Rogaine should only be applied to the scalp and in the recommended quantity. Excessive use does not increase efficacy but may increase the risk of systemic side effects.
Fuentes
La información médica de esta página se basa en las siguientes fuentes:
- European Medicines Agency (EMA). Minoxidil (topical) — Summary of Product Characteristics. Disponible en: ema.europa.eu
- World Health Organization (WHO). Model List of Essential Medicines. who.int
- Olsen EA, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377-385.
- Lucky AW, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50(4):541-553.
Este contenido se revisa periódicamente para reflejar las directrices clínicas actualizadas. Se proporciona únicamente con fines informativos y no constituye asesoramiento médico. Consulte siempre a un profesional sanitario cualificado para obtener asesoramiento relevante para sus circunstancias de salud individuales.
Frequently asked questions
- What is Rogaine used for?
- Rogaine (minoxidil) is approved for the topical treatment of androgenetic alopecia — hereditary hair loss — in both men and women. In men, it is used on the vertex (crown) of the scalp. In women, it is used for diffuse hair thinning across the top of the scalp. Rogaine is available as both a liquid solution and a foam formulation.
- How does Rogaine work?
- Minoxidil is a vasodilator — it widens blood vessels, increasing blood flow and nutrient delivery to hair follicles. It also prolongs the anagen (growth) phase of the hair cycle and stimulates follicle activity at the cellular level. Unlike finasteride, minoxidil does not reduce DHT levels. Its exact molecular mechanism in promoting hair growth is not fully characterised, but clinical evidence of efficacy is well established.
- How long does Rogaine take to work?
- Most users begin to notice a reduction in hair shedding within 2 to 3 months. Visible improvements in hair density typically take 4 to 6 months of consistent twice-daily application. Initial increased shedding (telogen effluvium) during the first 2 to 4 weeks of use is normal and indicates the follicles are transitioning — this is not a sign the treatment is failing.
- Can I get Rogaine online in Europe?
- Minoxidil topical products are available at various strengths. Lower-concentration formulations (2% and 5%) are available over-the-counter in many EU countries, while higher-strength formulations and oral minoxidil may require a prescription. Prescrivia connects patients with independent EU-registered doctors who can assess your suitability for minoxidil and issue a prescription where appropriate. We do not prescribe or dispense medicines directly.
- What is the difference between Rogaine solution and foam?
- Both the solution and foam contain minoxidil as the active ingredient. The foam formulation (5%) is generally considered easier to apply and less likely to cause scalp irritation from the propylene glycol carrier found in the liquid solution. Women may prefer the foam as it is less likely to cause facial hair growth when drips are managed carefully. The clinical efficacy of both formulations is comparable at equivalent concentrations.
Tratamientos
Prescrivia es únicamente una plataforma intermediaria. No prestamos servicios médicos, no prescribimos tratamientos ni dispensamos medicamentos. Todas las decisiones médicas son tomadas por médicos independientes registrados en la UE. Todos los medicamentos son dispensados por farmacias autorizadas de la UE. Esta plataforma facilita la conexión entre pacientes y profesionales sanitarios.